Homozygous Familial Hypercholesterolemia Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Homozygous Familial Hypercholesterolemia Market is segmented By Drug Type (PCSK9 Inhibitors, Mipomersen, Lomitapide), By Route of Administration (Subcutaneous, Oral), By ....

Homozygous Familial Hypercholesterolemia Market Size

Market Size in USD

CAGR8.2%

Study Period2024 - 2031
Base Year of Estimation2023
CAGR8.2%
Market ConcentrationHigh
Major PlayersAmgen Inc., Sanofi S.A., Regeneron Pharmaceuticals, Inc., Novartis AG, Ionis Pharmaceuticals, Inc.
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
setting-icon
Want to purchase customized report?
please let us know !

Homozygous Familial Hypercholesterolemia Market Analysis

The homozygous familial hypercholesterolemia market is estimated to be valued at USD 541.1 Mn in 2024 and is expected to reach USD 868.9 Mn by 2031, growing at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031. Innovation in treatment drugs coupled with increasing adoption of lipid apheresis procedures are estimated to drive the market during the forecast period.